UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Babesiosis: Treatment and prevention

Authors
Peter J Krause, MD
Edouard G Vannier, PhD
Section Editor
Johanna Daily, MD, MSc
Deputy Editor
Elinor L Baron, MD, DTMH

INTRODUCTION

Babesiosis is an infectious disease caused by protozoa of the genus Babesia and is transmitted primarily by tick vectors. Transmission rarely occurs via blood transfusion, organ transplantation, and congenitally. Babesia protozoa invade and cause lysis of red blood cells in mammalian hosts [1-3].

Babesia microti is the primary agent of human babesiosis in the United States, particularly in the Northeast and upper Midwest where it is endemic. Nearly all cases in Europe have been attributed to Babesia divergens, but the infection is sporadic. Babesia venatorum is endemic in northeastern China.

The treatment and prevention of babesiosis will be reviewed here. The clinical manifestations, diagnosis, microbiology, epidemiology, and pathogenesis of babesiosis are discussed separately. (See "Babesiosis: Clinical manifestations and diagnosis" and "Babesiosis: Microbiology, epidemiology, and pathogenesis".)

TREATMENT OF B. MICROTI INFECTION

Immunocompetent patients

Asymptomatic infection — Antimicrobial therapy should not be given to individuals with asymptomatic B. microti infection [4].

Mild to moderate disease — Mild to moderate babesiosis typically occurs in immunocompetent patients and is associated with parasitemia <4 percent; it does not require hospital admission. (See "Babesiosis: Clinical manifestations and diagnosis", section on 'Mild to moderate disease'.)

                      
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 13, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Vannier E, Krause PJ. Human babesiosis. N Engl J Med 2012; 366:2397.
  2. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North Am 2015; 29:357.
  3. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review. JAMA 2016; 315:1767.
  4. Centers for Disease Control and Prevention. Parasites - Babesiosis: Treatment. https://www.cdc.gov/parasites/babesiosis/health_professionals/index.html#tx (Accessed on September 15, 2017).
  5. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000; 343:1454.
  6. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.
  7. Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis 2001; 32:1117.
  8. White DJ, Talarico J, Chang HG, et al. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 1998; 158:2149.
  9. Kletsova EA, Spitzer ED, Fries BC, Marcos LA. Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone. Ann Clin Microbiol Antimicrob 2017; 16:26.
  10. Centers for Disease Control (CDC). Clindamycin and quinine treatment for Babesia microti infections. MMWR Morb Mortal Wkly Rep 1983; 32:65.
  11. Miller LH, Neva FA, Gill F. Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters. Ann Intern Med 1978; 88:200.
  12. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31:149.
  13. Spaete J, Patrozou E, Rich JD, Sweeney JD. Red cell exchange transfusion for babesiosis in Rhode Island. J Clin Apher 2009; 24:97.
  14. Saifee NH, Krause PJ, Wu Y. Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both? J Clin Apher 2016; 31:454.
  15. Stowell CP, Gelfand JA, Shepard JA, Kratz A. Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea. N Engl J Med 2007; 356:2313.
  16. Jacoby GA, Hunt JV, Kosinski KS, et al. Treatment of transfusion-transmitted babesiosis by exchange transfusion. N Engl J Med 1980; 303:1098.
  17. Yager PH, Luginbuhl LM, Dekker JP. Case records of the Massachusetts General Hospital. Case 6-2014. A 35-day-old boy with fever, vomiting, mottled skin, and severe anemia. N Engl J Med 2014; 370:753.
  18. Feder HM Jr, Lawlor M, Krause PJ. Babesiosis in pregnancy. N Engl J Med 2003; 349:195.
  19. El Khoury MY, Gandhi R, Dandache P, et al. Non-surgical management of spontaneous splenic rupture due to Babesia microti infection. Ticks Tick Borne Dis 2011; 2:235.
  20. Semel ME, Tavakkolizadeh A, Gates JD. Babesiosis in the immediate postoperative period after splenectomy for trauma. Surg Infect (Larchmt) 2009; 10:553.
  21. Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis 2010; 50:381.
  22. Lemieux JE, Tran AD, Freimark L, et al. A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse. Nat Microbiol 2016; 1:16079.
  23. Ranque S. The treatment of babesiosis. N Engl J Med 2001; 344:773.
  24. Shih CM, Wang CC. Ability of azithromycin in combination with quinine for the elimination of babesial infection in humans. Am J Trop Med Hyg 1998; 59:509.
  25. Falagas ME, Klempner MS. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Clin Infect Dis 1996; 22:809.
  26. Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. Clin Infect Dis 2007; 45:1588.
  27. Zintl A, Mulcahy G, Skerrett HE, et al. Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin Microbiol Rev 2003; 16:622.
  28. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46:370.
  29. Krause PJ, Spielman A, Telford SR 3rd, et al. Persistent parasitemia after acute babesiosis. N Engl J Med 1998; 339:160.
  30. Raffalli J, Wormser GP. Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis. Diagn Microbiol Infect Dis 2016; 85:231.
  31. Simon MS, Westblade LF, Dziedziech A, et al. Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti infection associated with Rituximab and Chronic Lymphocytic Leukemia. Clin Infect Dis 2017.
  32. Shaio MF, Yang KD. Response of babesiosis to a combined regimen of quinine and azithromycin. Trans R Soc Trop Med Hyg 1997; 91:214.
  33. Ord RL, Lobo CA. Human Babesiosis: Pathogens, Prevalence, Diagnosis and Treatment. Curr Clin Microbiol Rep 2015; 2:173.
  34. Raoult D, Soulayrol L, Toga B, et al. Babesiosis, pentamidine, and cotrimoxazole. Ann Intern Med 1987; 107:944.
  35. Beattie JF, Michelson ML, Holman PJ. Acute babesiosis caused by Babesia divergens in a resident of Kentucky. N Engl J Med 2002; 347:697.
  36. Herwaldt B, Persing DH, Précigout EA, et al. A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med 1996; 124:643.
  37. Herwaldt BL, de Bruyn G, Pieniazek NJ, et al. Babesia divergens-like infection, Washington State. Emerg Infect Dis 2004; 10:622.
  38. Persing DH, Herwaldt BL, Glaser C, et al. Infection with a babesia-like organism in northern California. N Engl J Med 1995; 332:298.
  39. Quick RE, Herwaldt BL, Thomford JW, et al. Babesiosis in Washington State: a new species of Babesia? Ann Intern Med 1993; 119:284.
  40. Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis 1997; 175:1259.
  41. Kjemtrup AM, Lee B, Fritz CL, et al. Investigation of transfusion transmission of a WA1-type babesial parasite to a premature infant in California. Transfusion 2002; 42:1482.
  42. Bloch EM, Herwaldt BL, Leiby DA, et al. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012; 52:1517.
  43. Häselbarth K, Tenter AM, Brade V, et al. First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen. Int J Med Microbiol 2007; 297:197.
  44. Herwaldt BL, Cacciò S, Gherlinzoni F, et al. Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe. Emerg Infect Dis 2003; 9:942.
  45. Blum S, Gattringer R, Haschke E, et al. The case: hemolysis and acute renal failure. Babesiosis. Kidney Int 2011; 80:681.
  46. Sun Y, Li SG, Jiang JF, et al. Babesia venatorum Infection in Child, China. Emerg Infect Dis 2014; 20:896.
  47. Jiang JF, Zheng YC, Jiang RR, et al. Epidemiological, clinical, and laboratory characteristics of 48 cases of "Babesia venatorum" infection in China: a descriptive study. Lancet Infect Dis 2015; 15:196.